Drugs / CLERVONAFUSP ALFA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02898753 | Jun 2017 → Mar 2020 | glycogen storage disease due to acid maltase deficiency, late-onset | Valerion Therapeutics, LLC | Terminated | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT05930223 | — | Lafora disease | Parasail, LLC | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLERVONAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594347 ↗ |
| Known as | VAL-1221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930223 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4594347 ↗ |
| Route | Intravenous | “Patients randomized to VAL-1221 will receive 7 intravenous (IV) infusions of VAL-1221” NCT02898753 ↗ |